Alzinova AB (ST:ALZ) — Market Cap & Net Worth
Market Cap & Net Worth: Alzinova AB (ALZ)
Alzinova AB (ST:ALZ) has a market capitalization of $4.97 Million (Skr46.16 Million) as of May 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #28380 globally and #642 in its home market, demonstrating a -23.31% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alzinova AB's stock price Skr0.44 by its total outstanding shares 104323588 (104.32 Million). Analyse Alzinova AB operating cash flow efficiency to see how efficiently the company converts income to cash.
Alzinova AB Market Cap History: 2019 to 2026
Alzinova AB's market capitalization history from 2019 to 2026. Data shows change from $151.56 Million to $4.97 Million (-43.49% CAGR).
Index Memberships
Alzinova AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$14.99 Billion | 0.03% | #197 of 281 |
Weight: Alzinova AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Alzinova AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alzinova AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1294.83x
Alzinova AB's market cap is 1294.83 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $151.56 Million | $6.81 Million | -$6.20 Million | 22.26x | N/A |
| 2020 | $86.45 Million | $14.90 Million | -$6.50 Million | 5.80x | N/A |
| 2021 | $72.30 Million | $17.32 Million | -$7.58 Million | 4.17x | N/A |
| 2022 | $31.10 Million | $16.63 Million | -$13.07 Million | 1.87x | N/A |
| 2023 | $34.07 Million | $270.00K | -$16.48 Million | 126.20x | N/A |
| 2024 | $38.85 Million | $30.00K | -$20.55 Million | 1294.83x | N/A |
Competitor Companies of ALZ by Market Capitalization
Companies near Alzinova AB in the global market cap rankings as of May 4, 2026.
Key companies related to Alzinova AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Alzinova AB Historical Marketcap From 2019 to 2026
Between 2019 and today, Alzinova AB's market cap moved from $151.56 Million to $ 4.97 Million, with a yearly change of -43.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr4.97 Million | -46.62% |
| 2025 | Skr9.31 Million | -76.04% |
| 2024 | Skr38.85 Million | +14.00% |
| 2023 | Skr34.07 Million | +9.57% |
| 2022 | Skr31.10 Million | -56.99% |
| 2021 | Skr72.30 Million | -16.36% |
| 2020 | Skr86.45 Million | -42.96% |
| 2019 | Skr151.56 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Alzinova AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.97 Million USD |
| MoneyControl | $4.97 Million USD |
| MarketWatch | $4.97 Million USD |
| marketcap.company | $4.97 Million USD |
| Reuters | $4.97 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Alzinova AB
Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, call… Read more